Brokerages Set Perspective Therapeutics, Inc. (NYSE:CATX) Target Price at $20.71

Perspective Therapeutics, Inc. (NYSE:CATX - Get Free Report) has earned a consensus recommendation of "Buy" from the nine research firms that are presently covering the firm, Marketbeat reports. Eight analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $21.43.

CATX has been the subject of a number of analyst reports. Wedbush assumed coverage on Perspective Therapeutics in a research note on Tuesday, October 1st. They set an "outperform" rating and a $25.00 price target for the company. Bank of America assumed coverage on Perspective Therapeutics in a report on Thursday, July 25th. They set a "buy" rating and a $24.00 price target for the company. Cantor Fitzgerald reissued an "overweight" rating on shares of Perspective Therapeutics in a research report on Monday, September 9th. Truist Financial started coverage on shares of Perspective Therapeutics in a research report on Wednesday, September 25th. They issued a "buy" rating and a $21.00 price objective for the company. Finally, Royal Bank of Canada dropped their target price on shares of Perspective Therapeutics from $29.00 to $27.00 and set an "outperform" rating on the stock in a research report on Friday, August 16th.

Perspective Therapeutics Stock Performance

CATX stock traded down $0.63 during trading on Friday, reaching $12.62. 5,182,972 shares of the stock were exchanged, compared to its average volume of 684,657. The business's 50 day simple moving average is $13.81. Perspective Therapeutics has a twelve month low of $2.20 and a twelve month high of $19.05.

Perspective Therapeutics (NYSE:CATX - Get Free Report) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.04. The business had revenue of $0.53 million for the quarter. Equities analysts predict that Perspective Therapeutics will post -0.87 earnings per share for the current year.

Institutional Trading of Perspective Therapeutics

Several hedge funds have recently made changes to their positions in the company. Victory Capital Management Inc. purchased a new stake in shares of Perspective Therapeutics during the 2nd quarter valued at approximately $117,000. Point72 DIFC Ltd purchased a new stake in shares of Perspective Therapeutics during the second quarter worth $118,000. SG Americas Securities LLC bought a new stake in shares of Perspective Therapeutics during the 3rd quarter valued at $246,000. The Manufacturers Life Insurance Company purchased a new stake in Perspective Therapeutics during the 2nd quarter worth about $188,000. Finally, Iowa State Bank bought a new position in Perspective Therapeutics in the 3rd quarter worth about $254,000. 54.66% of the stock is currently owned by institutional investors.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.